Cargando…

Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML

BACKGROUND: The impact of the dose intensity administered in consolidation in Latin America is unknown. This study aimed to evaluate the relative dose intensity (RDI) in consolidation and its impact in overall survival. METHODS: A retrospective study of 86 patients with AML who were diagnosed betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballesteros-Ramírez, Ricardo, Quijano, Sandra, Solano, Julio, Ordoñez-Reyes, Camila, Herrera, María V., Murillo, Raúl, Fiorentino, Susana, Arevalo-Zambrano, Mónica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333041/
https://www.ncbi.nlm.nih.gov/pubmed/32670373
http://dx.doi.org/10.1155/2020/8021095
_version_ 1783553664601817088
author Ballesteros-Ramírez, Ricardo
Quijano, Sandra
Solano, Julio
Ordoñez-Reyes, Camila
Herrera, María V.
Murillo, Raúl
Fiorentino, Susana
Arevalo-Zambrano, Mónica
author_facet Ballesteros-Ramírez, Ricardo
Quijano, Sandra
Solano, Julio
Ordoñez-Reyes, Camila
Herrera, María V.
Murillo, Raúl
Fiorentino, Susana
Arevalo-Zambrano, Mónica
author_sort Ballesteros-Ramírez, Ricardo
collection PubMed
description BACKGROUND: The impact of the dose intensity administered in consolidation in Latin America is unknown. This study aimed to evaluate the relative dose intensity (RDI) in consolidation and its impact in overall survival. METHODS: A retrospective study of 86 patients with AML who were diagnosed between 2010 and 2016 with a 2-year follow-up in a fourth-level Colombian hospital was carried out. Clinical characteristics were reported, Kaplan-Meier was used for estimating the overall survival, and Cox regression was used for multivariate analysis. RESULTS: The median overall survival (OS) was 20.83 months, and the median event-free survival (EFS) was 16.83 months. 64.3% of the patients achieved remission after the 7 + 3 chemotherapy induction treatment. Patients under 30 years of age, with white blood cell counts less than 100.000 cells/mm3 who responded to induction treatment had a better OS. Additionally, patients receiving an RDI greater than 0.75 of the planned consolidation dose had better survival. The prognostic variables with impact in the OS were the leukocyte count in peripheral blood at diagnosis, the RDI in consolidation treatment with HIDAC and the response obtained after induction. CONCLUSION: This retrospective study allowed us to know the epidemiology of AML in a reference Colombian Hospital. Additionally, in our knowledge, it is the first study that reports the RDI in consolidation with HIDAC in Latin America as a prognostic factor that directly impacts the OS.
format Online
Article
Text
id pubmed-7333041
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-73330412020-07-14 Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML Ballesteros-Ramírez, Ricardo Quijano, Sandra Solano, Julio Ordoñez-Reyes, Camila Herrera, María V. Murillo, Raúl Fiorentino, Susana Arevalo-Zambrano, Mónica J Cancer Epidemiol Research Article BACKGROUND: The impact of the dose intensity administered in consolidation in Latin America is unknown. This study aimed to evaluate the relative dose intensity (RDI) in consolidation and its impact in overall survival. METHODS: A retrospective study of 86 patients with AML who were diagnosed between 2010 and 2016 with a 2-year follow-up in a fourth-level Colombian hospital was carried out. Clinical characteristics were reported, Kaplan-Meier was used for estimating the overall survival, and Cox regression was used for multivariate analysis. RESULTS: The median overall survival (OS) was 20.83 months, and the median event-free survival (EFS) was 16.83 months. 64.3% of the patients achieved remission after the 7 + 3 chemotherapy induction treatment. Patients under 30 years of age, with white blood cell counts less than 100.000 cells/mm3 who responded to induction treatment had a better OS. Additionally, patients receiving an RDI greater than 0.75 of the planned consolidation dose had better survival. The prognostic variables with impact in the OS were the leukocyte count in peripheral blood at diagnosis, the RDI in consolidation treatment with HIDAC and the response obtained after induction. CONCLUSION: This retrospective study allowed us to know the epidemiology of AML in a reference Colombian Hospital. Additionally, in our knowledge, it is the first study that reports the RDI in consolidation with HIDAC in Latin America as a prognostic factor that directly impacts the OS. Hindawi 2020-06-24 /pmc/articles/PMC7333041/ /pubmed/32670373 http://dx.doi.org/10.1155/2020/8021095 Text en Copyright © 2020 Ricardo Ballesteros-Ramírez et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ballesteros-Ramírez, Ricardo
Quijano, Sandra
Solano, Julio
Ordoñez-Reyes, Camila
Herrera, María V.
Murillo, Raúl
Fiorentino, Susana
Arevalo-Zambrano, Mónica
Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML
title Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML
title_full Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML
title_fullStr Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML
title_full_unstemmed Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML
title_short Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML
title_sort influence of dose intensity in consolidation with hidac and other clinical and biological parameters in the survival of aml
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333041/
https://www.ncbi.nlm.nih.gov/pubmed/32670373
http://dx.doi.org/10.1155/2020/8021095
work_keys_str_mv AT ballesterosramirezricardo influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml
AT quijanosandra influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml
AT solanojulio influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml
AT ordonezreyescamila influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml
AT herreramariav influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml
AT murilloraul influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml
AT fiorentinosusana influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml
AT arevalozambranomonica influenceofdoseintensityinconsolidationwithhidacandotherclinicalandbiologicalparametersinthesurvivalofaml